COPD Management Guidelines

Introduction to LAMAs

• LAMAs are considered first-line maintenance therapy for COPD patients with persistent symptoms, preferred over LABAs due to superior exacerbation prevention properties, as recommended by the American Thoracic Society 1

LAMA Inhaler Options

• Common LAMA inhalers available in the UK include umeclidinium, tiotropium, glycopyrronium, and aclidinium, with varying dosing regimens, including once-daily and twice-daily options 1

Benefits of LAMAs

• LAMAs demonstrate significant benefits in COPD management, including improved lung function and quality of life compared to placebo, as reported in the Chest journal in 2015 1

Contraindications and Precautions

• Beta-blockers, including eye drop formulations, should be avoided as they can worsen bronchospasm, according to the British Thoracic Society 2

Treatment Optimization

• Regular review is essential to assess treatment response, side effects, and continued appropriateness of the device, ensuring optimal COPD management, as recommended by the National Institute for Health and Care Excellence and the European Respiratory Society 1, 3
• For most patients with COPD, a LAMA/LABA combination inhaler is the preferred maintenance treatment option, with progression to triple therapy (ICS/LABA/LAMA) for those with frequent exacerbations or persistent symptoms 3
• Short-acting bronchodilators, such as SABA or SAMA, can be used as needed for symptom relief in patients with COPD 2
• Long-acting bronchodilators, including LAMA or LABA monotherapy, are available options for COPD management, with LAMAs generally preferred over LABAs due to their superior exacerbation prevention 3, 1
• Triple therapy, consisting of ICS/LABA/LAMA, is recommended for patients with continued exacerbations despite LAMA/LABA therapy, with common UK options including fluticasone furoate/umeclidinium/vilanterol 3
• For exacerbations of COPD, treatment strategies include:
• Proper inhaler technique is crucial for effective COPD management and should be demonstrated and checked regularly to avoid reduced drug delivery and treatment failure 2
• ICS-containing inhalers increase the risk of pneumonia and should be reserved for patients with frequent exacerbations, with consideration of stepping down the ICS component if the patient has been stable for 3 months and the initial indication was unclear 2
• Home nebulizer therapy should only be prescribed after formal assessment by a respiratory specialist 2